RNXT RSI Chart
Last 7 days
-5.5%
Last 30 days
15.1%
Last 90 days
-0.7%
Trailing 12 Months
-36.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 26, 2024 | spiegel robert j. | bought | - | - | 40,983 | - |
Jan 26, 2024 | marton laurence | bought | - | - | 8,196 | - |
Jan 26, 2024 | bagai shaun | bought | - | - | 40,983 | chief executive officer |
Jan 26, 2024 | agah ramtin | bought | - | - | 40,983 | chief medical officer |
Jan 26, 2024 | macfarlane k. angela | bought | - | - | 40,983 | - |
Oct 03, 2023 | nelms angela | bought | 1,150 | 1.04634 | 1,100 | chief operating officer |
Nov 03, 2022 | marton laurence | acquired | 43,244 | 1.7 | 25,438 | - |
Jun 07, 2022 | agah ramtin | bought | 10,001 | 1.93 | 5,182 | chief medical officer |
May 19, 2022 | bagai shaun | bought | 11,275 | 2.05 | 5,500 | chief executive officer |
Mar 16, 2022 | agah ramtin | gifted | - | - | 975,000 | chief medical officer |
Which funds bought or sold RNXT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -270 | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -17,909 | 25,262 | -% |
May 15, 2024 | Royal Bank of Canada | added | 31.68 | - | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 36.31 | -2,132 | 8,400 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 20.32 | -37,805 | 89,924 | -% |
May 13, 2024 | HRT FINANCIAL LP | sold off | -100 | -32,000 | - | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 2.99 | -61.00 | 92.00 | -% |
May 10, 2024 | VANGUARD GROUP INC | added | 0.28 | -53,536 | 76,028 | -% |
May 10, 2024 | BlackRock Inc. | reduced | -2.56 | -21,053 | 27,926 | -% |
May 09, 2024 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | unchanged | - | -46,770 | 65,971 | -% |
Unveiling RenovoRx, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to RenovoRx, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
RenovoRx, Inc. News
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
Assets | 226.6% | 4,788 | 1,466 | 3,519 | 6,314 | 4,561 | 7,265 | 9,250 | 11,243 | 13,946 | 16,287 | 18,178 | 1,914 |
Current Assets | - | - | - | - | - | - | 7,265 | 9,250 | 11,243 | 13,943 | 16,281 | 18,164 | 1,910 |
Cash Equivalents | 265.8% | 4,389 | 1,200 | 3,200 | 6,000 | 3,700 | 4,391 | 3,093 | 2,769 | 13,121 | 15,192 | 17,725 | 1,795 |
Liabilities | -32.4% | 3,021 | 4,466 | 3,513 | 5,126 | 1,305 | 1,102 | 1,102 | 1,123 | 1,406 | 938 | 625 | 4,119 |
Current Liabilities | -7.0% | 1,093 | 1,175 | 1,605 | 1,699 | - | 1,102 | - | - | - | 938 | 625 | 4,096 |
Shareholder's Equity | 158.9% | 1,767 | -3,000 | 6.00 | 1,188 | 3,256 | 6,163 | 8,148 | 10,120 | 12,540 | 15,349 | 17,553 | - |
Retained Earnings | -2.6% | -42,481 | -41,400 | -38,200 | -36,800 | -34,430 | -31,173 | -29,017 | -26,881 | -24,300 | -21,284 | -18,900 | -14,960 |
Additional Paid-In Capital | 15.2% | 44,246 | 38,404 | 38,183 | 37,944 | 37,685 | 37,318 | 37,151 | 37,004 | 36,826 | 36,632 | 36,481 | 303 |
Shares Outstanding | 57.7% | 16,866 | 10,694 | 10,693 | 10,693 | 9,131 | 9,098 | 9,039 | 9,025 | 8,992 | 8,934 | 5,620 | 2,233 |
Float | - | - | - | - | 15,500 | - | - | - | 15,500 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Cashflow From Operations | -7.4% | -2,204 | -2,053 | -2,728 | -2,771 | -2,706 | -1,681 | -2,672 | -2,361 | -2,097 | -2,558 | -1,119 | -1,247 | -992 | - | - |
Share Based Compensation | 91.4% | 423 | 221 | 239 | 257 | 361 | 164 | 143 | 169 | 168 | 126 | 6.00 | 7.00 | 8.00 | - | 7.00 |
Cashflow From Investing | - | - | - | - | - | 2,032 | 2,976 | 2,992 | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | 5,420 | - | - | 5,002 | 6.00 | 3.00 | 4.00 | 9.00 | 26.00 | 25.00 | 17,287 | 1,982 | 34.00 | - | - |
Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 1,257 | $ 1,338 |
General and administrative | 1,219 | 1,923 |
Total operating expenses | 2,476 | 3,261 |
Loss from operations | (2,476) | (3,261) |
Other income/(expenses), net: | ||
Interest and dividend income | 37 | 4 |
Change in fair value of common warrant liability | 1,363 | |
Total other income/(expenses), net | 1,400 | 4 |
Net loss | $ (1,076) | $ (3,257) |
Net loss per share, basic | $ (0.07) | $ (0.36) |
Net loss per share, diluted | $ (0.07) | $ (0.36) |
Weighted-average shares of common stock outstanding, basic | 14,947,500 | 9,089,989 |
Weighted-average shares of common stock outstanding, diluted | 14,947,500 | 9,089,989 |
Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,389 | $ 1,173 |
Prepaid expenses and other current assets | 271 | 192 |
Deferred offering costs | 128 | 101 |
Total assets | 4,788 | 1,466 |
Current liabilities: | ||
Accounts payable | 356 | 561 |
Accrued expenses | 737 | 614 |
Total current liabilities | 1,093 | 1,175 |
Common stock warrant liability | 1,928 | 3,291 |
Total liabilities | 3,021 | 4,466 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2024, and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024, and December 31, 2023 | ||
Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2024, and December 31, 2023; 16,865,975 and 10,693,580 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively | 2 | 1 |
Additional paid-in capital | 44,246 | 38,404 |
Accumulated deficit | (42,481) | (41,405) |
Total stockholders’ equity | 1,767 | (3,000) |
Total liabilities and stockholders’ equity | $ 4,788 | $ 1,466 |